Histologic, immunophenotypic, and PCR findings in KSHV MCD
Case no. . | HIV . | EBV . | Diagnosis and KSHV-associated lesions . | Plasmablasts . | KSHV LNA . | KSHV* vIL6 . | Plasmablasts Ig . | Fr3-JH . | Fr3-Jλ . |
---|---|---|---|---|---|---|---|---|---|
MCD | P | P | |||||||
1 | − | − | Microlymphoma (Sp) | + | + | + | IgMλ | M | M |
Plasmablastic lymphoma (LN) | M | M | |||||||
MCD | P | P | |||||||
2 | + | − | Microlymphoma (Sp) | + | + | + | IgMλ | P | P |
MCD | P | P | |||||||
3 | − | − | Microlymphoma (LN) | + | + | + | IgMλ | P | P |
MCD | P | P | |||||||
4 | + | − | Microlymphoma (Sp) | + | + | + | IgMλ | M | M |
MCD | P | P | |||||||
5 | + | − | Microlymphoma (Sp) | + | + | + | IgMλ | P | P |
Plasmblastic lymphoma (LN) | M | P | |||||||
MCD | P | P | |||||||
6 | + | − | Microlymphoma (Sp) | + | + | ND | IgMλ | P | P |
MCD | P | P | |||||||
7 | + | − | Microlymphoma (Sp) | + | + | ND | IgMλ | P | ND |
MCD | ND | ND | |||||||
8 | + | − | Microlymphoma (Sp) | + | + | ND | IgMλ | ND | ND |
MCD | P | ND | |||||||
9 | + | − | Microlymphoma (LN) | + | + | + | IgMλ | P | ND |
10 | + | − | MCD | + | + | + | IgMλ | P | ND |
11 | + | − | MCD | + | + | ND | IgMλ | P | P |
12 | + | − | MCD | + | + | + | IgMλ | P | P |
13 | + | − | MCD | + | + | ND | IgMλ | P | ND |
Case no. . | HIV . | EBV . | Diagnosis and KSHV-associated lesions . | Plasmablasts . | KSHV LNA . | KSHV* vIL6 . | Plasmablasts Ig . | Fr3-JH . | Fr3-Jλ . |
---|---|---|---|---|---|---|---|---|---|
MCD | P | P | |||||||
1 | − | − | Microlymphoma (Sp) | + | + | + | IgMλ | M | M |
Plasmablastic lymphoma (LN) | M | M | |||||||
MCD | P | P | |||||||
2 | + | − | Microlymphoma (Sp) | + | + | + | IgMλ | P | P |
MCD | P | P | |||||||
3 | − | − | Microlymphoma (LN) | + | + | + | IgMλ | P | P |
MCD | P | P | |||||||
4 | + | − | Microlymphoma (Sp) | + | + | + | IgMλ | M | M |
MCD | P | P | |||||||
5 | + | − | Microlymphoma (Sp) | + | + | + | IgMλ | P | P |
Plasmblastic lymphoma (LN) | M | P | |||||||
MCD | P | P | |||||||
6 | + | − | Microlymphoma (Sp) | + | + | ND | IgMλ | P | P |
MCD | P | P | |||||||
7 | + | − | Microlymphoma (Sp) | + | + | ND | IgMλ | P | ND |
MCD | ND | ND | |||||||
8 | + | − | Microlymphoma (Sp) | + | + | ND | IgMλ | ND | ND |
MCD | P | ND | |||||||
9 | + | − | Microlymphoma (LN) | + | + | + | IgMλ | P | ND |
10 | + | − | MCD | + | + | + | IgMλ | P | ND |
11 | + | − | MCD | + | + | ND | IgMλ | P | P |
12 | + | − | MCD | + | + | + | IgMλ | P | P |
13 | + | − | MCD | + | + | ND | IgMλ | P | ND |
MCD indicates multicentric Castleman disease; LN, lymph node; Sp, spleen; P, polyclonal; M, monoclonal; ND, not done.
KSHV vIL-6 was expressed in 10% to 15% of KSHV-positive plasmablasts.